HOME >> BIOLOGY >> NEWS
Another great boost to medical research

Medicines Australia has welcomed today's announcement by the Minister for Health and Ageing, Tony Abbott, of $5 million in grants to 21 of Australia's leading medical research teams.

The grants have been awarded under special programs of the National Health and Medical Research Council designed to promote collaboration between Australia's researchers and high technology medical research industries.

The grants are headlined by a $90,500 grant to the research team of Australian of the Year, Professor Ian Frazer. The grant to Professor Frazer's team at the University of Queensland will be invested in research into the development of better therapeutic vaccines to fight cancer.

The Chief Executive Officer of Medicines Australia, Mr Kieran Schneemann, said the latest round of grants build on the Federal Government's announcement in the recent Budget that it will invest an additional $905 million in health and medical research during the next four years.

"This latest announcement is another building block toward furthering Australia's worldleading health and medical research sector," Mr Schneemann said.

"Australia has had some stunning recent successes in health and medical research - highlighted by the pending launch of the world first vaccine for cervical cancer.

"The benefits of investing in health and medical research are leading to real benefits for Australian patients.

"The success of our health and medical research requires a partnership between government, researchers and industry - today's announcement is the latest example of the success of our Australian partnership," Mr Schneemann said.

Medicines Australia also welcomed the even distribution of the grants across Australia - with grants going to researchers in five states and one territory.

It also congratulates Professor Frazer for becoming a joint winner of the prestigious William B Coley prize for distinguished research in tumour imm
'"/>

Contact: Paul Chamberlin
61-419-233-989
Research Australia
31-May-2006


Page: 1 2

Related biology news :

1. Another sexual attraction is possible ...
2. Another world-first for LCTs Xeno facilities
3. Another boost for stem cell research
4. Another grape excuse to hit the bottle
5. Another gene rearrangement involved in prostate cancer identified
6. Another world-record achievement for National High Magnetic Field Laboratory
7. Acid rain and forest mass: Another perspective
8. Clones on task serve greater good, evolutionary study shows
9. Genetic analysis finds greater threat in frog-killing fungus
10. Chitin from lobster shell shows great healing and bio-stimulant properties
11. A small leak will sink a great ship

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Another great boost medical research

(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: